Kamada Ltd.
HealthcareNASDAQ:KMDA · NASDAQ Global Select
+$0.00 today
Vol 0.03M · Avg 0.06M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$181.7M of revenue converted into $20.4M of net income for the selected period. Gross margin is 41.1% and net margin is 11.2%, showing how much revenue survives after costs and taxes. EPS is $0.35, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $180.5M +12.1% | $161.0M +12.9% | $142.5M +10.2% | $129.3M +24.8% | $103.6M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $104.1M +14.4% | $91.0M +4.5% | $87.0M +5.3% | $82.6M +12.7% | $73.3M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $76.4M +9.2% | $70.0M +26.1% | $55.5M +18.8% | $46.7M +54.0% | $30.3M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 42.3% -1.1pp | 43.5% +4.5pp | 38.9% +2.8pp | 36.1% +6.8pp | 29.3% | 9.8% | 28.9% | 38.3% |
| Research & Development | $13.0M -14.4% | $15.2M +9.0% | $13.9M +5.8% | $13.2M +16.0% | $11.4M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $33.8M +9.8% | $30.8M +12.3% | $27.4M +9.5% | $25.1M +42.8% | $17.6M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $50.2M +0.5% | $49.9M +9.9% | $45.4M +7.7% | $42.2M +35.9% | $31.0M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $14.9M +8.0% | $13.8M +20.4% | $11.5M -5.6% | $12.2M +116.7% | $5.6M | $374.2M | $1.2B | $631.8M |
| EBITDA | $39.2M +41.2% | $27.8M +31.2% | $21.2M +96.1% | $10.8M +169.8% | $4.0M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 21.7% +4.5pp | 17.3% +2.4pp | 14.9% +6.5pp | 8.4% +4.5pp | 3.9% | 5.6% | 46.3% | 42.0% |
| Operating Income | $26.2M +30.8% | $20.1M +99.2% | $10.1M +122.1% | $4.5M +751.1% | -$696.0K | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 14.5% +2.1pp | 12.5% +5.4pp | 7.1% +3.6pp | 3.5% +4.2pp | -0.7% | 16.6% | 24.1% | 22.0% |
| Interest Income | $1.9M -9.3% | $2.1M +260.2% | $588.0K +546.2% | $91.0K -69.2% | $295.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $864.0K +30.9% | $660.0K -49.2% | $1.3M +42.0% | $914.0K +223.0% | $283.0K | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$2.8M +58.8% | -$6.7M -310.8% | -$1.6M +75.9% | -$6.8M -471.2% | -$1.2M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $23.5M +76.0% | $13.3M +58.2% | $8.4M +473.1% | -$2.3M -19.8% | -$1.9M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 13.0% +4.7pp | 8.3% +2.4pp | 5.9% +7.7pp | -1.7% +0.1pp | -1.8% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $3.3M +389.8% | -$1.1M -877.9% | $145.0K +133.9% | $62.0K -82.0% | $345.0K | $1.3B | -$1.6B | $745.2M |
| Net Income | $20.2M +39.7% | $14.5M +74.6% | $8.3M +456.9% | -$2.3M -4.1% | -$2.2M | $4.9B | $4.8B | $4.7B |
| Net Margin | 11.2% +2.2pp | 9.0% +3.2pp | 5.8% +7.6pp | -1.8% +0.4pp | -2.2% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $0 +52.0% | $0 +47.1% | $0 +428.2% | -$0 -4.0% | -$0 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $0 +48.0% | $0 +66.7% | $0 +389.6% | -$0 -4.0% | -$0 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $57.6M +0.3% | $57.5M +17.7% | $48.8M +9.0% | $44.8M +0.1% | $44.8M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $58.3M +0.9% | $57.8M +7.7% | $53.7M +19.8% | $44.8M +0.1% | $44.8M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Tactile Systems Technology, Inc.
NASDAQ:TCMD
$593.46M
Solid Biosciences Inc.
NASDAQ:SLDB
$556.28M
XOMA Royalty Corp.
NASDAQ:XOMA
$524.09M
Evolus, Inc.
NASDAQ:EOLS
$443.20M
PureTech Health plc
NASDAQ:PRTC
$424.07M
Auna S.A.
NYSE:AUNA
$364.93M
Semler Scientific, Inc.
SMLR
$310.75M
Rocket Pharmaceuticals, Inc.
NASDAQ:RCKT
$300.28M
Quantum-Si incorporated
NASDAQ:QSI
$187.28M
Galectin Therapeutics Inc.
NASDAQ:GALT
$175.84M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does KMDA generate?
Kamada Ltd. (KMDA) reported $180.46M of revenue in fiscal 2025.
Is KMDA profitable?
Kamada Ltd. (KMDA) reported $20.20M of net income, with a net margin of 11.2%.
Explore More
Continue the stock analysis
Jump to another research area for this company.